Supplementary Figure 3 from A prognostic model based on residual cancer burden and tumor-infiltrating lymphocytes on residual disease after neoadjuvant therapy in HER2+ breast cancer

Supplementary Figure 3 – Matched evaluation of baseline TIL (b-TILs) and residual (RD-TILs) in the overall RD cohort (Fig. 3a), the high RD-TILs cohort (Fig. 3b) and in the low RD-TILs cohort (Fig. 3c).